CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|October 15, 2020
- BioPharm International-10-15-2020
- Volume 2020 eBook
- Issue 3
Tackling Cybersecurity Challenges in Legacy Systems
Author(s)Robert Brokamp, Adi Karisik
Ongoing and emerging cyber-risks to legacy operational technology systems in bio/pharmaceutical manufacturing must be addressed.
Advertisement
As bio/pharma manufacturers make their operations and networks increasingly streamlined and interconnected, there is a need to connect older facilities to the supply chain. In turn, this means that operational technology (OT) cybersecurity measures must be introduced to legacy systems to support archaic equipment, older operating systems, and decades-old protocols as well as networks where it is not possible to fully monitor the operational network or to detect and control intrusions.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 28–30
Citation
When referring to this article, please cite it as R. Brokamp and A. Karisik, “Tackling Cybersecurity Challenges in Legacy Systems," BioPharm International Regulatory Sourcebook (October 2020).
Articles in this issue
almost 6 years ago
Bio/Pharma Industry Works Overtime to Find COVID-19 Therapiesalmost 6 years ago
GMPs Guide COVID-19 Vaccine Manufacturingalmost 6 years ago
Viral Vector API Characterization of Product-Related Impuritiesalmost 6 years ago
Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?almost 6 years ago
Enhancing Process Validation for Sterile Liquid and Freeze-Dried Formsalmost 6 years ago
Due Diligence Assessment of CMC Activitiesalmost 6 years ago
Strong Quality Culture: A How-To for Busy Managersalmost 6 years ago
Resources, Guidelines, and Guidance Documentsalmost 6 years ago
Regulatory and Standard Setting OrganizationsAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement